Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J OLIVER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1679501431
CMS profile
121491
Location
BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,343.06

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,278.11 62
Education $64.95 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 63 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J OLIVER

NPI 1679501431 · CMS profile ID 121491

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 63 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679501431?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 63 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501431?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 63 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501431?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 63 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1679501431?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $1,343.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $25.1612/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031821909 CMS
Novo Nordisk Inc $18.6512/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943249 CMS
Astellas Pharma US Inc $18.4212/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034718575 CMS
GlaxoSmithKline, LLC. $24.1811/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466483 CMS
Novo Nordisk Inc $21.4911/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943301 CMS
GlaxoSmithKline, LLC. $22.2911/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466475 CMS
Xeris Pharmaceuticals, Inc. $14.0411/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056485469 CMS
Kowa Pharmaceuticals America, Inc. $14.0311/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003817891 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.4210/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997130645 CMS
Novo Nordisk Inc $2.4010/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943183 CMS
ABBVIE INC. $13.4610/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998042731 CMS
PFIZER INC. $21.2410/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049641087 CMS
Novo Nordisk Inc $22.6310/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943325 CMS
Lilly USA, LLC $12.8010/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032026325 CMS
E.R. Squibb & Sons, L.L.C. $13.5409/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016236557 CMS
Novo Nordisk Inc $21.2009/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943289 CMS
GlaxoSmithKline, LLC. $20.4109/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466467 CMS
ABBVIE INC. $14.8309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998042729 CMS
GlaxoSmithKline, LLC. $16.4109/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467253 CMS
Bayer Healthcare Pharmaceuticals Inc. $13.3908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000239807 CMS
Astellas Pharma US Inc $64.9508/28/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034452893 CMS
Novo Nordisk Inc $14.9208/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943221 CMS
AstraZeneca Pharmaceuticals LP $12.7608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014964787 CMS
E.R. Squibb & Sons, L.L.C. $13.3008/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016236485 CMS
Lilly USA, LLC $18.9508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031843219 CMS
Amgen Inc. $18.4807/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020030763 CMS
Abbott Laboratories $16.5107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018803557 CMS
Novo Nordisk Inc $23.4107/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943353 CMS
IDORSIA PHARMACEUTICALS US INC $19.3107/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034526151 CMS
GlaxoSmithKline, LLC. $21.4707/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003467517 CMS
GlaxoSmithKline, LLC. $21.4606/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466479 CMS
PFIZER INC. $14.0106/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050565881 CMS
Lilly USA, LLC $20.8606/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031926987 CMS
Novo Nordisk Inc $20.3306/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943273 CMS
Amgen Inc. $14.2906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020641895 CMS
GlaxoSmithKline, LLC. $17.7506/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466371 CMS
SANOFI-AVENTIS U.S. LLC $14.9505/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050015287 CMS
ABBVIE INC. $22.4605/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998042727 CMS
Novo Nordisk Inc $3.9005/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943197 CMS
Novo Nordisk Inc $22.3605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943313 CMS
E.R. Squibb & Sons, L.L.C. $22.1704/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016236409 CMS
Lilly USA, LLC $20.0004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032026321 CMS
Novo Nordisk Inc $103.7304/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943407 CMS
Novo Nordisk Inc $17.2604/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943235 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.7004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996963885 CMS
Novo Nordisk Inc $23.5504/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000943363 CMS
PFIZER INC. $17.8504/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050586269 CMS
Astellas Pharma US Inc $12.7504/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034035655 CMS
ABBVIE INC. $12.7703/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998042725 CMS
GlaxoSmithKline, LLC. $20.6503/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003466799 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,982.16 111
PY2020 $387.82 28
PY2021 $1,408.56 66
PY2022 $1,192.77 60
PY2023 $1,343.06 63
PY2024 $1,223.14 62
PY2025 $1,203.19 61

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,083,959.47 12
PY2024 Recipient $43,914.50 5
PY2024 Principal investigator $1,015,962.54 15
PY2023 Recipient $195.00 1
PY2023 Principal investigator $828,848.21 14
PY2022 Recipient $34,661.00 4
PY2022 Principal investigator $514,412.47 14
PY2021 Principal investigator $507,716.92 33
PY2020 Recipient $5,278.97 8
PY2020 Principal investigator $291,944.00 17
PY2019 Recipient $10,899.97 2
PY2019 Principal investigator $442,530.95 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $22,950.00 11/27/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038149361
Principal investigator 1 Eli Lilly and Company $3,018.56 10/01/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1038141459
Principal investigator 1 Eli Lilly and Company $104,115.00 05/15/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038155775
Recipient Eli Lilly and Company $195.00 04/28/2023 Covered Recipient Physician A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038054013
Principal investigator 1 Eli Lilly and Company $1,750.00 04/24/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038151951
Principal investigator 1 Eli Lilly and Company $3,750.00 04/10/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED PHASE 3 OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) No dispute reported 06/30/2026 1038146879
Principal investigator 1 Eli Lilly and Company $4,560.82 02/21/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038151939
Principal investigator 1 Eli Lilly and Company $2,981.76 02/07/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 1038149899
Principal investigator 1 Eli Lilly and Company $14,966.98 01/26/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1038151945
Principal investigator 1 Eli Lilly and Company $313,439.00 01/13/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038149879
Principal investigator 1 Eli Lilly and Company $3,293.02 01/10/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038149355
Principal investigator 1 Eli Lilly and Company $45,661.10 01/04/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1038149893
Principal investigator 1 Eli Lilly and Company $146,434.00 01/03/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS No dispute reported 06/30/2026 1038146887
Principal investigator 1 Eli Lilly and Company $60,373.00 01/03/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1038149887
Principal investigator 1 Eli Lilly and Company $101,554.97 01/03/2023 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3 MULTICENTER RANDOMIZED PARALLEL-DESIGN OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1038155769